30.05.2014 - (idw) Veterinrmedizinische Universitt Wien

Janus kinases (JAKs) are proteins that can promote the growth of cancer cells. The protein JAK2 is of special therapeutic significance: its inactivation is believed to destroy cancer cells. However, the effect of JAK2 inhibition on healthy blood stem cells is so far unknown. Scientists at the Vetmeduni Vienna show that the loss of JAK2 in the mouse causes healthy blood stem cells to disappear while cancer cells preserve their growth potential. Future studies will address the question as to whether these data can be passed on to treatment in humans. The results were published in the journal Leukemia. As a new therapeutic approach, Janus kinases are currently in the limelight of cancer research. The focus of interest is the protein JAK2. By inhibiting this protein one tries to cure chronic bone marrow diseases, such as myelofibrosis and chronic myeloid leukemia (CML).

Loss of JAK2 is advantageous for leukemia cells

Scientists working with Veronika Sexl at the Institute of Pharmacology and Toxicology may initiate a transformation of thought in regard of JAK2 inhibition. To simulate the human disease as accurately as possible, the scientists used a mouse leukemia model. In an experiment, mice received blood cancer cells as well as healthy hematopoietic stem cells in which JAK2 had been removed. "In mice, the absence of JAK2 accelerated the course of leukemia drastically," the scientists concluded.

The loss of JAK2 caused healthy hematopoietic stem cells to disappear in mice. "Leukemic cells, on the other hand, remained entirely unaffected; they do not need JAK2. This led to an imbalance in which the number of leukemia cells was very predominant, and eventually caused the acceleration of leukemia," says Eva Grundschober, one of the lead authors.

"The oncogene BCR-ABL, which was present in mice with leukemia, does not appear to require JAK2 for its activity. However, JAK2 is essential for healthy cells," explains Andrea Hlbl-Kovacic, the other lead author.

A closer investigation of healthy stem cells supports this hypothesis. In the absence of JAK2, healthy stem cells cannot survive and reproduce blood cells. As the next step, the following question will be raised in Sexl's laboratory: how does JAK2 mediate its life-sustaining effect on healthy stem cells? What portions of the JAK2 protein are required for this purpose and are these affected by current therapies?

The article Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2, by Eva Grundschober, Andrea Hlb-Kovacic, Neha Bhagwat, Boris Kovacic, Ruth Scheicher, Eva Eckelhart, Karoline Kollmann, Matthew Keller, Florian Grebien, Kay-Uwe Wagner, Ross L. Levine and Veronika Sexl was published today in the journal Leukemia. doi:10.1038/leu.2014.152 http://www.nature.com/leu/journal/vaop/naam/abs/leu2014152a.html

About the University of Veterinary Medicine, Vienna The University of Veterinary Medicine, Vienna in Austria is one of the leading academic and research institutions in the field of Veterinary Sciences in Europe. About 1,200 employees and 2,300 students work on the campus in the north of Vienna which also houses five university clinics and various research sites. Outside of Vienna the university operates Teaching and Research Farms. http://www.vetmeduni.ac.at

Scientific Contact: Prof. Veronika Sexl

Read more here:
One cell's meat is another cell's poison